A Phase II and Biomarker Study of Tivozanib With Gemcitabine Addition Upon Progression in Patients With Metastatic Refractory Renal Cell Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2013
At a glance
- Drugs Gemcitabine (Primary) ; Tivozanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Biomarker
- 10 Jun 2017 Biomarkers information updated
- 30 Jun 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Jun 2013 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.